ARCA Biopharma hints at future fundraising or merger move in latest earnings
WESTMINSTER — ARCA Biopharma Inc. (Nasdaq: ABIO) said it’s open to another funding round, merger or takeover offer Wednesday as it plans for a pivotal final clinical trial in its flagship drug.
The Westminster-based gene therapy company for heart conditions posted a loss of 76 cents per share, beating Wall Street estimates of a $1.30 per share loss, according to Seeking Alpha data. The company did not report revenue.
It posted a $1.156 million loss for the quarter, compared to $1.59 million in the same period last year.
In its filings with the U.S. Securities…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
Columbine Health Systems will host Dementia Week, a series of free events devoted to educating…
-
Boulder Community Health this month became the first facility in Colorado to offer patients a…
-
Nextera Healthcare LLC and ImagineMD have combined to form a single direct-primary-care organization for employer…
